ovarian%20cancer
OVARIAN CANCER
Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.

    Introduction

    • Seventh most common cancer in women (excluding skin cancer)
    • Leading cause of death from gynecologic cancer in developed countries
    • Has 3 histologic types:
      • Epithelial ovarian cancer - primarily seen in women >50 years of age
      • Germ cell ovarian cancer - more commonly seen in women <20 years of age
      • Sex cord stromal ovarian cancer - rare; produces steroid hormones 
    • Median age at the time of diagnosis is 63 years and >70% present with advanced disease

    Risk Factors

    Increased Risk

    • Family history
      • Associated with an early-onset disease
        • Patients having ≥2 first-degree relatives with ovarian cancer
        • Male breast cancer
        • Bilateral or early-onset (<50 years old) breast cancer
        • Personal or family history of colon or endometrial cancer
    • Genetic syndromes
      • Associated with early-onset disease
        • BRCA 1 mutations have a lifetime risk of 26-51% of developing ovarian cancer
        • BRCA 2 mutations have a lifetime risk of 10-23% of developing ovarian cancer
        • Lynch syndrome (hereditary nonpolyposis colorectal cancer) has a lifetime risk of 10%
        • Cowden’s disease has increased risk of ovarian cancer due to mutations in PTEN gene
        • Peutz-Jeghers Syndrome secondary to mutations in STK11 gene
        • MUTYH-associated polyposis secondary to mutations in gene MUTYH
    • Age
      • Risk of developing ovarian cancer gets higher with age and is most prevalent in the eighth decade of life
    • Reproductive history
      • Nulliparity or age >35 years at first childbirth
      • Early menarche
      • Late menopause
    • Personal history of breast cancer
      • Risk of ovarian cancer after breast cancer is highest in women with a family history of breast cancer
    • Obesity
      • Obese women with a body mass index of at least 30 kg/m2 have a higher risk of developing ovarian cancer
    • Fertility drugs
      • Some studies show that using the fertility drug Clomiphene citrate for >1 year increased the risk of developing low malignant-potential ovarian tumors
      • Risk was shown to be highest in women who did not get pregnant while receiving the drug
    • Estrogen therapy
      • Studies have shown that postmenopausal women using estrogen monotherapy for at least 5-10 years have a higher risk of developing ovarian cancer
    • Pelvic inflammatory disease (PID)
      • May increase the risk for ovarian cancer
    • In vitro fertilization (IVF)
      • The risk of borderline ovarian cancer may be increased after ovarian stimulation for IVF
    • Androgens
      • A study had shown that women who took androgens were found to have a higher risk of ovarian cancer
    • Talcum powder
      • Some studies suggest a very slight increase in risk of ovarian cancer in women who used talc on their genital area

    Decreased Risk

    • Reproductive history
      • Younger age at pregnancy and at first childbirth (≤25 years old) has 30-60% lower risk
    • Oral contraceptive use for >5 years significantly lowers the risk of ovarian cancer
    • Breastfeeding has 30-60% lower risk
    • Diet
      • A study had shown that low fat diet for at least 4 years had a lower risk for ovarian cancer
    • Gynecologic surgery (eg hysterectomy, prophylactic oophorectomy, tubal ligation)
      • Tubal ligation may reduce the chance of developing ovarian cancer for up to 67%
    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
    DOWNLOAD
    Editor's Recommendations
    Most Read Articles
    27 Nov 2017
    Transdermal oestradiol added to progesterone reduces menopause-related depression, researchers reported at the annual meeting of The North American Menopause Society in Philadelphia, US.
    5 days ago
    Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.
    Tracy TC Kwan, BSc (Nursing), MPH; Hextan YS Ngan, MBBS, FHKAM (O&G), MD (HK), FRCOG, 01 Aug 2013

    Human papillomavirus (HPV) infection is a prevalent disease worldwide. Consequences of HPV infection vary, depending on the infected individuals and the HPV genotype involved. Life-threatening consequences are not uncommon, and cervical cancer is a clear demonstration of the virus’s potency. While the incidence of cervical cancer is heavily concentrated on developing countries,1 the impact of HPV-related diseases on developed countries has not ceased. In the United States alone, HPV infections are the most common sexually transmitted disease with an estimated 5 million new cases being diagnosed in 2000 among young adults, incurring nearly US$3 billion in terms of direct medical costs.2 A multinational study involving 18,498 women showed that cervical HPV prevalence varied greatly geographically, ranging from the low of 1.6% in North Vietnam to the high of 27% in Nigeria. In general, HPV prevalence peaked among young, sexually active women and declined with age. In selected countries, however, a second peak was noted in women older than 55 years.3 The high prevalence of HPV-related diseases incurs a heavy burden on the healthcare systems of developed and developing countries alike, which renders HPV research and prevention a global public health imperative. On an individual level, the afflictions caused by HPV-related diseases go beyond that of physical suffering to affecting the psychological well-being of the infected. This is the focus of our paper.

    27 Nov 2017
    Chronic hepatitis B virus (HBV) infection is a global problem. Chronic HBV infection is probably the most common maternal infection encountered in Hong Kong, China, and Southeast Asia. In Hong Kong, which is one of the endemic areas, immunisation against HBV was first provided in 1983 to infants born to mothers who were screened positive for hepatitis B surface antigen (HBsAg). Immunisation became widespread since November 1988, but HBsAg-positive mothers are still encountered frequently.1